Salud financiera de hoja de balance de Alembic Pharmaceuticals
Salud financiera controles de criterios 6/6
Alembic Pharmaceuticals tiene un patrimonio de accionistas total de ₹48.9B y una deuda total de ₹9.9B, lo que sitúa su ratio deuda-patrimonio en 20.4%. Sus activos y pasivos totales son ₹72.3B y ₹23.4B respectivamente. El BAIT de Alembic Pharmaceuticals es de ₹7.2B, por lo que su ratio de cobertura de intereses es de 12.9. Tiene efectivo e inversiones a corto plazo que ascienden a ₹1.3B.
Información clave
20.4%
Ratio deuda-patrimonio
₹9.95b
Deuda
| Ratio de cobertura de intereses | 12.9x |
| Efectivo | ₹1.29b |
| Patrimonio | ₹48.88b |
| Total pasivo | ₹23.43b |
| Activos totales | ₹72.30b |
Actualizaciones recientes sobre salud financiera
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹37.6B) de APLLTD superan a sus pasivos a corto plazo (₹21.7B).
Pasivo a largo plazo: Los activos a corto plazo de APLLTD (₹37.6B) superan a sus pasivos a largo plazo (₹1.7B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (17.7%) de APLLTD se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de APLLTD ha pasado de 51.8% a 20.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de APLLTD está bien cubierta por el flujo de caja operativo (41.1%).
Cobertura de intereses: Los pagos de intereses de la deuda de APLLTD están bien cubiertos por el BAIT (12.9x cobertura).